Article
Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.
Current neurology and neuroscience reports - 1 Oct 2011
Comabella Manuel, Vandenbroeck Koen
Abstract excerpt
Notwithstanding the availability of disease-modifying treatments including interferon-β, glatiramer acetate, and natalizumab, a considerable proportion of multiple sclerosis (MS) patients experience continued progression of disease, clinical relapses, disease activity on MRI, and adverse effects. Application of gene expression, proteomic or genomic approaches is universally accepted as a suitable strategy toward...
Topics
Join the communities discussing this publication.